Pulmonary tuberculosis: Difference between revisions
From IDWiki
m (Text replacement - "Category:TB" to "Category:Tuberculosis") |
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
||
Line 3: | Line 3: | ||
* See [[Mycobacterium tuberculosis]] |
* See [[Mycobacterium tuberculosis]] |
||
== Clinical |
== Clinical Manifestations == |
||
* Presents as reactivation of latent infection months or years after [[Mycobacterium tuberculosis#Primary tuberculosis|primary tuberculosis]] |
* Presents as reactivation of latent infection months or years after [[Mycobacterium tuberculosis#Primary tuberculosis|primary tuberculosis]] |
||
* Subacute or [[chronic cough]] (at least 2 to 3 weeks) eventually becoming productive and occasionally involving [[hemoptysis]] |
* Subacute or [[chronic cough]] (at least 2 to 3 weeks) eventually becoming productive and occasionally involving [[hemoptysis]] |
Revision as of 13:43, 19 July 2020
Background
Microbiology
Clinical Manifestations
- Presents as reactivation of latent infection months or years after primary tuberculosis
- Subacute or chronic cough (at least 2 to 3 weeks) eventually becoming productive and occasionally involving hemoptysis
- Should be suspected in any patient with cough and HIV infection
- Constitutional symptoms, with fevers, night sweats, and unexplained weight loss
- Usually from reactivation of latent tuberculosis infection, and usually reactivates in lung apices
- May transiently improve with partially-active antibiotics such as fluoroquinolones
Investigations
- Spontaneous sputum, induced sputum, or bronchoalveolar lavage specimens should be sent for
- Acid-fast staining of a smear
- Culture
- PCR
Management
- Empiric treatment for suspected drug-susceptible tuberculosis is RIPE x2mo then RI x4mo
- Isoniazid 5mg/kg/d, max 300mg daily, with pyridoxine 25 mg po daily
- Rifampin 10mg/kg/d
- Pyrazinamide 25mg/kg/d, max 2g daily
- Ethambutol 20mg/kg/d, max 1.2g daily, which can be dropped once susceptibility testing shows that it is pan-susceptible
- Standard duration for uncomplicated disease is 6 months total, though it is extended if high risk of relapse (see below)
- Treatment for multidrug-resistant tuberculosis is discussed separately
Special populations
- For the elderly, or those at elevated risk of hepatotoxicity: can do induction phase without pyrazinamide and extend continuation phase to 7 months (from 4)
- For pregnant women: can consider dropping pyrazinamide and extending the course by 3 months, but if there is severe disease then likely should follow standard treatment
- For high risk of relapse, including extensive or cavitary disease in the first 2 months of treatment, culture-positivity after 2 months of treatment, or cavitary disease on CXR at end of treatment: the consolidation phase should be extended by 3 months (to 9 months total treatment)
- For severe liver disease:
- Avoid rifampin, isoniazid, and pyrazinamide
- Recommend a fluoroquinolone, ethambutol, and amikacin for 2 months followed by fluroquinolone and ethambutol for 18 months
- Can consider adding rifampin if they are monitored closely
Infection control
- Airborne precautions until:
- Treated for at least 2 weeks and symptoms are clearly improving
- 3x negative sputum smears
- They can be discharged home when clinical improvement, drug-resistant TB is not suspected and there is no contraindication for home isolation